Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios inversely correlate to clinical and pathologic stage in patients with resectable pancreatic ductal adenocarcinoma

Documenti analoghi

• Analyzing outcomes of neoadjuvant and adjuvant treatment for borderline-resectable pancreatic adenocarcinoma in the perioperative period at an academic institution
  di: Recio-Boiles, Alejandro, et al.
  Pubblicazione: (2020)
• Evaluation of the safety and effectiveness of direct oral anticoagulants and low molecular weight heparin in gastrointestinal cancer-associated venous thromboembolism
  di: Recio-Boiles, Alejandro, et al.
  Pubblicazione: (2019)
• Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC)
  di: Babiker, Hani M, et al.
  Pubblicazione: (2019)
• Neutrophil to lymphocyte ratio, not platelet to lymphocyte or lymphocyte to monocyte ratio, is predictive of patient survival after resection of early-stage pancreatic ductal adenocarcinoma
  di: Pointer, David T., et al.
  Pubblicazione: (2020)
• Identifying the role of neutrophil-to-lymphocyte ratio and platelets-to-lymphocyte ratio as prognostic markers in patients undergoing resection of pancreatic ductal adenocarcinoma
  di: Giakoustidis, Alexandros, et al.
  Pubblicazione: (2018)